A first-in-human trial of intravesical BH011, a novel docetaxel formulation, in patients with high risk non-muscle invasive bladder cancer (HR-NMIBC) after BCG failure: Results from a phase 1 study.
Corrected: This story has been updated to note that the cancellation of contracts to develop U.S. Department of Education’s What Works Clearinghouse practice guides affected at least two guides that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results